Drugs / NST-628
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06326411 | Apr 2024 → Nov 2028 expected | glioma, melanoma, non-small cell lung carcinoma | Nested Therapeutics, Inc | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NST-628 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06326411 ↗ |
| Modality | Small molecule | “NST-628 is a small molecule” NCT06326411 ↗ |
| Route | Oral | “Successive cohorts of subjects will receive escalating doses of NST-628 orally once daily in 28-day cycles.” NCT06326411 ↗ |